News
27m
Asianet Newsable on MSNNovo Nordisk Downgraded By UBS Over Uncertain Outlook For Wegovy, But Retail Prefers To Look At The Sunny Side
UBS downgraded Novo Nordisk to ‘Neutral’ from ‘Buy’ with a price target of DKK 340 ($52.59), down from DKK 600. The new price target still implies a near 9% upside to the stock’s closing price on ...
President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...
(Reuters) -Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss ...
The telehealth company posted revenue of $544.8 million in the second quarter, marking a 73% increase year over year but missing analyst estimates for $552 million, according to Bloomberg data. Hims & ...
Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results